Table 1.
Association between Sp1 expression and clinicopathological parameters in nasopharyngeal carcinoma patients
| Sp1 expression level | ||||
|---|---|---|---|---|
|
|
||||
| All cases | Low expression | High expression | P value | |
| Age | 0.182 | |||
| ≥ 50 yeara | 44 | 23 (53.5%) | 22 (56.4%) | |
| < 50 year | 38 | 20 (46.5%) | 17 (43.6%) | |
| Gender | 0.342 | |||
| Male | 55 | 29 (67.4%) | 23 (59.0%) | |
| Female | 27 | 14 (32.6%) | 16 (41.0%) | |
| Tumor stage | 0.001 | |||
| T1 | 12 | 9 (20.9%) | 3 (7.7%) | |
| T2 | 28 | 20 (46.5%) | 8 (20.5%) | |
| T3 | 26 | 9 (20.9%) | 17 (43.6%) | |
| T4 | 16 | 5 (11.7%) | 11 (28.2%) | |
| Nodal status | 0.008 | |||
| N0 | 22 | 16 (37.2%) | 6 (15.4%) | |
| N1 | 31 | 20 (46.5%) | 11 (28.2%) | |
| N2 | 22 | 5 (11.6%) | 17 (43.6%) | |
| N3 | 7 | 2 (4.7%) | 5 (12.8%) | |
| Clinical stage | 0.008 | |||
| I | 6 | 4 (9.3%) | 2 (5.2%) | |
| II | 24 | 19 (44.2%) | 5 (12.8%) | |
| III | 29 | 12 (27.9%) | 17 (43.6%) | |
| IV | 23 | 8 (18.6%) | 15 (38.4%) | |
| Distant metastasis | 0.008 | |||
| M0 | 63 | 38 (88.3%) | 25 (64.1%) | |
| M1 | 19 | 5 (11.7%) | 14 (35.9%) | |
a
Mean age;
WHO, World Health Organization; Sp1 expression was determined by immunohistochemical analysis.